# A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer

> **NCT01647789** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 31 (actual)

## Conditions studied

- Prostatic Neoplasms

## Interventions

- **DRUG:** CFG920

## Key facts

- **NCT ID:** NCT01647789
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-12-04
- **Primary completion:** 2016-02-03
- **Final completion:** 2016-02-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2018-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01647789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01647789, "A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01647789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*